SG10201803042PA - Anti-tim-3 antibodies - Google Patents

Anti-tim-3 antibodies

Info

Publication number
SG10201803042PA
SG10201803042PA SG10201803042PA SG10201803042PA SG10201803042PA SG 10201803042P A SG10201803042P A SG 10201803042PA SG 10201803042P A SG10201803042P A SG 10201803042PA SG 10201803042P A SG10201803042P A SG 10201803042PA SG 10201803042P A SG10201803042P A SG 10201803042PA
Authority
SG
Singapore
Prior art keywords
antibodies
tim
disclosed
title
methods
Prior art date
Application number
SG10201803042PA
Inventor
Cheng-I Wang
Hsueh Ling Janice Oh
Siok Ping Yeo
Yun Pei Sharon Goh
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201419089A external-priority patent/GB201419089D0/en
Priority claimed from GB201419092A external-priority patent/GB201419092D0/en
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG10201803042PA publication Critical patent/SG10201803042PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Abstract

Title: Anti-TIM-3 Antibodies Anti-TIM-3 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same. Figure 1
SG10201803042PA 2014-10-27 2015-10-27 Anti-tim-3 antibodies SG10201803042PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201419089A GB201419089D0 (en) 2014-10-27 2014-10-27 Anti-TIM-3 antibodies
GB201419092A GB201419092D0 (en) 2014-10-27 2014-10-27 Anti-TIM-3 antibodies

Publications (1)

Publication Number Publication Date
SG10201803042PA true SG10201803042PA (en) 2018-06-28

Family

ID=55857945

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201703403TA SG11201703403TA (en) 2014-10-27 2015-10-27 Anti-tim-3 antibodies
SG10201803042PA SG10201803042PA (en) 2014-10-27 2015-10-27 Anti-tim-3 antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201703403TA SG11201703403TA (en) 2014-10-27 2015-10-27 Anti-tim-3 antibodies

Country Status (9)

Country Link
US (2) US10259874B2 (en)
EP (1) EP3212231B1 (en)
JP (1) JP6709215B2 (en)
KR (1) KR20170075778A (en)
CN (2) CN110294807B (en)
AU (1) AU2015340056A1 (en)
CA (1) CA2965960A1 (en)
SG (2) SG11201703403TA (en)
WO (1) WO2016068803A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3212231B1 (en) * 2014-10-27 2021-04-28 Agency For Science, Technology And Research Anti-tim-3 antibodies
GB201419094D0 (en) * 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
EP3265486A4 (en) 2015-03-06 2018-11-14 Sorrento Therapeutics, Inc. Antibody therapeutics that bind tim3
EP3337826A1 (en) 2015-08-20 2018-06-27 Sutro Biopharma, Inc. Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
SG11201810023QA (en) 2016-05-27 2018-12-28 Agenus Inc Anti-tim-3 antibodies and methods of use thereof
JP7461741B2 (en) 2016-06-20 2024-04-04 カイマブ・リミテッド Anti-PD-L1 and IL-2 Cytokines
AU2017297506A1 (en) 2016-07-14 2019-02-21 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
JOP20190013A1 (en) * 2016-08-25 2019-01-31 Lilly Co Eli Anti-tim-3 antibodies
CN109790218B (en) * 2016-08-26 2023-03-03 百济神州有限公司 anti-TIM-3 antibodies and uses thereof
JP7265984B2 (en) * 2016-10-21 2023-04-27 アディマブ， エルエルシー Anti-respiratory syncytial virus antibodies and methods of their production and use
JOP20190133A1 (en) * 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd Anti-tim-3 antibodies for combination with anti-pd-1 antibodies
CN108264557B (en) * 2016-12-30 2021-08-24 惠和生物技术(上海)有限公司 Bifunctional molecule combining CD3 and T cell negative co-stimulatory molecule and application thereof
US11046764B2 (en) 2017-01-03 2021-06-29 Trellis Bioscience, Llc Native human antibodies for immune checkpoint modulation targets TIM-3 and B7-H3
EP3574019A4 (en) 2017-01-26 2021-03-03 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
EP4039274A1 (en) 2017-07-28 2022-08-10 Phanes Therapeutics, Inc. Anti-tim-3 antibodies and uses thereof
SG11202001211TA (en) 2017-08-28 2020-03-30 Bristol Myers Squibb Co Tim-3 antagonists for the treatment and diagnosis of cancers
TWI800552B (en) 2017-11-10 2023-05-01 新加坡科技研究局 Il2rbeta/common gamma chain antibodies
WO2019140229A1 (en) * 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
US20210363242A1 (en) 2018-01-16 2021-11-25 Bristol-Myers Squibb Company Methods of treating cancer with antibodies against tim3
EP3758751A4 (en) * 2018-02-28 2021-11-17 Wuxi Biologics Ireland Limited. Monoclonal antibody against human lag-3, method for preparing same, and use thereof
CN110272489B (en) * 2018-03-15 2023-08-22 上海健信生物医药科技有限公司 Fully humanized antibody molecule, antigen binding fragment and medical application thereof aiming at TIM-3
CN110305216B (en) * 2018-03-20 2022-09-02 无锡智康弘义生物科技有限公司 Novel anti-TIM-3 antibodies
PE20210665A1 (en) 2018-03-23 2021-03-31 Bristol Myers Squibb Co ANTIBODIES AGAINST MICA AND / OR MICB AND ITS USES
CN111989341B (en) * 2018-04-12 2023-06-02 南京维立志博生物科技有限公司 Antibodies that bind TIM-3 and uses thereof
WO2019206095A1 (en) * 2018-04-24 2019-10-31 安源医药科技（上海）有限公司 Antibody against tim-3 and application thereof
CA3103629A1 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
EA202190056A1 (en) * 2018-06-19 2021-05-28 Ридженерон Фармасьютикалз, Инк. ANTIBODIES AGAINST FACTOR XII / XIIa AND THEIR APPLICATION
CA3104868A1 (en) * 2018-07-09 2020-01-16 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
TW202031683A (en) 2018-11-09 2020-09-01 新加坡商優其洛伊生物私人有限公司 Il2rbeta/common gamma chain antibodies
US20220119545A1 (en) * 2018-11-09 2022-04-21 Beth Israel Deaconess Medical Center Cdcp1-targeted therapies
TW202039557A (en) 2018-11-09 2020-11-01 新加坡商優其洛伊生物私人有限公司 Il2rbeta/common gamma chain antibodies
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
EP3976831A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
CN114127315A (en) 2019-05-30 2022-03-01 百时美施贵宝公司 Method of identifying subjects suitable for immunooncology (I-O) therapy
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
CN110498855A (en) * 2019-07-25 2019-11-26 钟小泉 A kind of TIM-3 antibody and application thereof
CN110922478B (en) * 2019-12-07 2021-07-30 中国人民解放军军事科学院军事医学研究院 Fully human monoclonal antibody against chikungunya fever and application thereof
JP2023509359A (en) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド Combination anticancer therapy with inducers of iron-dependent cell degradation
WO2021169948A1 (en) * 2020-02-24 2021-09-02 苏州恒康生命科学有限公司 Tim3 binding molecule and application thereof
KR102572804B1 (en) * 2020-02-25 2023-08-31 국립암센터 Method of providing information for diagnosing or predicting prognosis cancer measuring the TIM-3 expression level in CD11b+ cell
CN116096906A (en) 2020-06-29 2023-05-09 旗舰创业创新五公司 Virus engineered to promote saenox delivery and use thereof in treating cancer
WO2022047412A1 (en) 2020-08-31 2022-03-03 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
CN112094348B (en) * 2020-09-22 2021-11-30 首都医科大学附属北京胸科医院 Anti-human Tim3 antibody or functional fragment thereof and application thereof
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
WO2022146948A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
IL303648A (en) 2020-12-28 2023-08-01 Bristol Myers Squibb Co Antibody compositions and methods of use thereof
JP2024504162A (en) * 2021-01-22 2024-01-30 エルピス・バイオファーマシューティカルズ Bispecific chimeric antigen receptor that binds CD19 and CD22
EP4083065A1 (en) * 2021-01-28 2022-11-02 NantBio, Inc. Anti-tim3 monoclonal antibodies and chimeric antigen receptors
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
KR20240026507A (en) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. Immune cells engineered to promote thananotransmission and uses thereof
CN114181311B (en) * 2021-12-20 2023-06-20 华东师范大学 Fully human anti-DLL 3 scFv and application thereof in CART cell therapy
WO2023168195A2 (en) * 2022-03-04 2023-09-07 The Scripps Research Institute Human broadly neutralizing antibodies against betacoronaviruses
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6113396A (en) 1995-06-14 1997-01-15 Regents Of The University Of California, The Novel high affinity human antibodies to tumor antigens
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
ES2192426B1 (en) 2000-05-11 2005-02-16 Universidad De Vigo SM50 / 20 HUMAN MONOCLONAL ANTIBODY RECOGNIZING HUMAN LEUKOCYTES, AND THEIR USE IN THERAPY.
ES2347239T3 (en) 2002-12-02 2010-10-27 Amgen Fremont Inc. ANTIBODIES DIRECTED TO THE TUMOR NECROSIS FACTOR AND USES OF THE SAME.
EP3000886A1 (en) 2003-03-19 2016-03-30 Amgen Fremont Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
EP1685159B1 (en) * 2003-10-03 2012-08-01 Brigham & Women's Hospital Tim-3 polypeptides
US8128929B2 (en) 2005-06-17 2012-03-06 Imclone Llc Antibodies against PDGFRa
CA2629453C (en) 2005-11-10 2018-03-06 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
EP2252319A2 (en) * 2008-01-29 2010-11-24 The Brigham and Women's Hospital, Inc. Methods for modulating a population of myeloid-derived suppressor cells and uses thereof
WO2010014854A2 (en) 2008-07-31 2010-02-04 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
JP2012508017A (en) 2008-11-07 2012-04-05 ファブラス エルエルシー Anti-DLL4 antibody and use thereof
ES2571235T3 (en) 2009-04-10 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedure for the treatment of a blood tumor that uses the anti-TIM-3 antibody
EP2558497A2 (en) 2010-04-15 2013-02-20 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
KR101846590B1 (en) * 2010-06-11 2018-04-09 교와 핫꼬 기린 가부시키가이샤 Anti-tim-3 antibody
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
WO2013006490A2 (en) * 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
EP2543680A1 (en) * 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
CN102392038B (en) 2011-11-01 2013-04-17 浙江大学 Expression vector for deleting exogenous genes in polished rice of transgenic rice and application thereof
CN102492038B (en) 2011-12-09 2014-05-28 中国人民解放军军事医学科学院基础医学研究所 Anti-human Tim-3 neutralized monoclonal antibody L3D and application thereof
CA2916638C (en) 2012-07-31 2021-01-12 The Brigham And Women's Hospital, Inc. Modulation of the immune response
EP3586874A1 (en) * 2012-08-14 2020-01-01 IBC Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CN103665164A (en) * 2012-10-24 2014-03-26 中国人民解放军军事医学科学院基础医学研究所 ELISA (enzyme-linked immunosorbent assay) kit for detecting Tim-3
WO2014070874A1 (en) 2012-10-31 2014-05-08 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
JP2014162739A (en) * 2013-02-22 2014-09-08 National Institute Of Biomedical Innovation Bispecific antibody and pharmaceutical composition
US10519251B2 (en) * 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
CN103936853B (en) * 2014-01-26 2016-08-17 中国人民解放军军事医学科学院基础医学研究所 A kind of detection TIM-3 test kit and using method thereof
JOP20200096A1 (en) * 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
EP3212231B1 (en) 2014-10-27 2021-04-28 Agency For Science, Technology And Research Anti-tim-3 antibodies
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
CN104592388B (en) * 2015-03-02 2017-05-31 中国人民解放军总医院 A kind of antigen-binding portion thereof of the monoclonal antibody of anti-human Tim 3

Also Published As

Publication number Publication date
US20170240633A1 (en) 2017-08-24
KR20170075778A (en) 2017-07-03
WO2016068803A1 (en) 2016-05-06
EP3212231B1 (en) 2021-04-28
CN107405397A (en) 2017-11-28
US11142574B2 (en) 2021-10-12
CN107405397B (en) 2020-08-25
SG11201703403TA (en) 2017-05-30
US20190185564A1 (en) 2019-06-20
EP3212231A1 (en) 2017-09-06
AU2015340056A1 (en) 2017-05-25
CN110294807A (en) 2019-10-01
EP3212231A4 (en) 2018-03-28
CN110294807B (en) 2023-05-12
JP2017536111A (en) 2017-12-07
CA2965960A1 (en) 2016-05-06
JP6709215B2 (en) 2020-06-10
US10259874B2 (en) 2019-04-16

Similar Documents

Publication Publication Date Title
SG10201803042PA (en) Anti-tim-3 antibodies
MX2019007021A (en) Il-11ra antibodies.
MY191581A (en) Anti-pd-1 antibodies
MX2019007020A (en) Il-11 antibodies.
IL262497A (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2021006235A (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof.
ZA201806576B (en) Antibodies, pharmaceutical compositions and methods
IL268588A (en) Anti-gprc5d antibodies, compositions comprising same and uses thereof
MX2020009649A (en) Monoclonal antibodies against bcma.
MY191035A (en) Affinity-oligonucleotide conjugates and uses thereof
MX2017003478A (en) Anti-fgfr2/3 antibodies and methods using same.
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
PH12016502142B1 (en) Anti-ptk7 antibody-drug conjugates
EP3186277A4 (en) Antibodies, compositions, and uses
WO2016094837A3 (en) Anti-c10orf54 antibodies and uses thereof
SG10201804931QA (en) Anti-cll-1 antibodies and immunoconjugates
WO2016077381A8 (en) Anti-interleukin-33 antibodies and uses thereof
WO2015200902A8 (en) Endophytes, associated compositions, and methods of use thereof
SG10201808259TA (en) Anti-jagged1 antibodies and methods of use
HK1256414A1 (en) Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
EP3129048A4 (en) Antibodies, pharmaceutical compositions and uses thereof
WO2016044463A3 (en) Mk2 inhibitors and uses thereof
WO2015179658A3 (en) Anti-gpc3 antibodies and immunoconjugates
MX2016004802A (en) Anti-rsp02 and/or anti-rsp03 antibodies and their uses.
SG10201907901XA (en) Antibodies, uses & methods